ArticleBMC chemistry2025
Design, synthesis, biological evaluation, and computational insights of 2-(Aryl)benzo[d]imidazo[2,1-b]thiazole-7-sulfonamide derivatives as potent antitubercular and antibacterial agents.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- N-(1H-Indazolyl) Aryl Sulfonamide Hybrids as Potential Dihydropteroate Synthase Inhibitors: In Vitro Antibacterial Activity Against Escherichia coli and Staphylococcus aureus and Computational Modeling.Chemistry & biodiversity · 2026Article
- A theoretical study on the corrosion inhibition of Cu surfaces using 4-amino-3-thioxo-6-methyl-1,2,4-triazine-5-one and its derivatives.Scientific reports · 2025Article
- Furan-thiazole hydrazone scaffolds as promising antitubercular and antibacterial agents: synthesis, characterization, bioevaluation and computational analysis.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of 2-(aryl)benzo[d]imidazo[2,1-b]thiazole-7-sulfonamide derivatives were synthesized and evaluated for their antitubercular and antibacterial activities, molecular docking, and DFT studies. The compounds were synthesized through a multi-step reactions, with yields varying based on the electronic and steric effects of the substituents. Among the derivatives, 5b, 5d, and 5h exhibited potent antitubercular activity against Mycobacterium tuberculosis (H37Rv strain) with minimum inhibitory concentrations (MICs) of 1.6 µg/mL, comparable to some standard drugs like isoniazid. Antibacterial testing revealed that 2-(2,4-dichlorophenyl)benzo[d]imidazo[2,1-b]thiazole-7-sulfonamide displayed significant activity against Gram-positive bacteria, with MICs as low as 6.25 µg/mL for Staphylococcus aureus and Bacillus subtilis. The molecular docking and DFT analyses provided insights into the binding interactions and electronic structures of these compounds, with halogen substitutions enhancing biological activity due to increased electron-withdrawing effects. MESP studies showed a distinct electron density distribution, supporting the observed bioactivity. For antitubercular activity, compounds 5b, 5d, and 5h demonstrated potent binding affinities (-6.2 to -5.9 kcal/mol) against the DprE1 enzyme. Compound 5f showed remarkable antibacterial efficacy, with a docking score of -7.9 kcal/mol against 2,2-dialkylglycine decarboxylase The DFT analysis revealed that 5a, with a methoxy substituent, had the highest reactivity (ΔE = 3.86 eV), while halogenated derivatives, such as 5f, exhibited increased chemical stability (ΔE = 4.24 eV). ADME studies showed that 5f having favorable lipophilicity and enzyme inhibition. These findings suggested that these derivatives could serve as potential candidates for further drug development against bacterial and mycobacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.